Article By:
ChinaBio® Today
Saturday, February 25, 2023 3:20 PM EDT
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between InnoCare and Biogen for an MS drug has been unwound.
The World Has Turned Sunny
I don't really understand why $BGNE was downrated. The news was positive.